A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics of XH-S003 After Single and Multiple Ascending Doses, Plus the Evaluation of Food Effects in Healthy Volunteers
Latest Information Update: 22 Nov 2024
At a glance
- Drugs XH S003 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors S-Infinity Pharmaceuticals
- 18 Nov 2024 Status changed from recruiting to completed.
- 16 Jan 2024 Planned number of patients changed from 72 to 64, interventional study model has been changed to sequential Assignment.
- 16 Jan 2024 Planned End Date changed from 16 Jun 2024 to 30 Aug 2024.